Biodextris, a leading Contract Development and Manufacturing Organization (CDMO) rooted in the legacy of GSK’s biologics and vaccine operations and backed by the healthcare-focused private equity firm ArchiMed, is proud to announce the appointment of Dr. Behzad Mahdavi as Executive Chairman. In this role, Dr. Mahdavi will also lead the company’s global commercial expansion, serving as Chief Commercial Officer.
With more than 25 years of leadership experience in the CDMO and CRO sectors—including senior roles at Lonza, Catalent Pharma Solutions, and Ginkgo Bioworks—Dr. Mahdavi brings a proven track record of commercial innovation, global market development, and value-driven growth across the biopharmaceutical landscape. His appointment marks a pivotal moment for Biodextris as it advances its mission to become a world-class provider of end-to-end development and manufacturing services for biologics (mammalian and microbial), vaccines, and advanced therapeutic modalities.
Also Read: Veeva and the Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
“With our scientific heritage, top-tier talent, and a purpose-built, versatile GMP facility, Biodextris is uniquely positioned to help companies overcome the challenges of scaling complex biologics and emerging modalities,” said Dr. Behzad Mahdavi. “My objective is to make Biodextris the partner of choice for innovative pharma and cell engineering companies-scaling early breakthroughs from bench to batch, quickly and reliably, with a flexible and approachable team that truly understands the science behind each product and embraces innovation.”
“We are thrilled to welcome Dr. Mahdavi to Biodextris,” said Cédric Héroux, CEO of Biodextris. “His global commercial acumen and strategic vision come at a pivotal time as we expand our state-of-the-art GMP facility. His leadership will be instrumental in strengthening our position as a trusted international partner in biologics development.”
SOURCE: PRNewswire